Extended Dose Ipilimumab With a Peptide Vaccine: Immune Correlates Associated With Clinical Benefit in Patients With Resected High-Risk Stage IIIc/IV Melanoma
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-10-2463
Full Text
Open PDFAbstract
Available in full text
Date
November 24, 2010
Authors
Publisher
American Association for Cancer Research (AACR)